Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jul 21, 2022; 28(27): 3476-3487
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3476
Figure 1
Figure 1 Flow diagram of the patient selection process. GIST: Gastrointestinal stromal tumor; HALP: Combination index of hemoglobin, albumin, lymphocyte, and platelet; WBC: White blood cell.
Figure 2
Figure 2 Kaplan-Meier curves of recurrence-free survival. A: Stratified by low/high levels of the combination index of hemoglobin, albumin, lymphocyte, and platelet (HALP) in gastrointestinal stromal tumors (GISTs) patients before propensity scores matching (PSM); B: Stratified by low/high levels of HALP in GIST patients after PSM; C: Stratified by low/high levels of HALP in high-risk GIST patients. GIST: Gastrointestinal stromal tumors; PSM: Propensity scores matching; HALP: Hemoglobin, albumin, lymphocyte, and platelet.
Figure 3
Figure 3 Comparison of hemoglobin, albumin, lymphocyte, and platelet and other parameters in prediction ability of 5-year recurrence-free survival by receiver operating characteristic curve analysis before propensity scores matching. AUC: Area under the curve; HALP: Hemoglobin, albumin, lymphocyte, and platelet; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic nutritional index; PSM: Propensity scores matching; ROC: Receiver operating characteristic.